Re:SpaceX Revenue Doubled to $4.6B in 2022 Versus 2021
by jeffreyrogers on Thursday August 17, 2023 @05:15PM
(#37168197)
Wait until you learn about the biotech industry, they often go public with no revenue. I don't think there is anything wrong with this though, markets are pricing future growth, which may or may not materialize.
[ Parent
| on HN ]
Re:SpaceX Revenue Doubled to $4.6B in 2022 Versus 2021
by getoffmycase on Thursday August 17, 2023 @05:43PM
(#37168531)
Biotech and drug discovery is inherently gambling. Most May tank, but some have the potential to 10-20x. Traditionally their IPOs allowed them to spread the risk out broadly amongst the public. Then they somehow became stupidly overvalued in 2020-2021
Re:SpaceX Revenue Doubled to $4.6B in 2022 Versus 2021
by htss2013 on Friday August 25, 2023 @08:43PM
(#37268806)
I actually think this makes sense. It's basically outsourced R&D for pharma companies via acquisition of companies once they get at or near approval of a new drug.
This is why I don't take seriously any stats about pharma R&D spending. They don't consider acquisitions to be R&D even though it often effecively is.